|Bid||1.2700 x 1200|
|Ask||1.2800 x 1200|
|Day's Range||1.2500 - 1.3300|
|52 Week Range||1.1100 - 2.9600|
|Beta (3Y Monthly)||0.44|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 17, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.00|
WALTHAM, Mass., Oct. 17, 2018 -- NeuroMetrix, Inc. (Nasdaq: NURO), today reported financial and business highlights for the quarter ended September 30, 2018. The Company.
NEW YORK, NY / ACCESSWIRE / October 17, 2018 / NeuroMetrix, Inc. (NASDAQ: NURO ) will be discussing their earnings results in their 2018 Third Quarter Earnings to be held on October 17, 2018 at 8:00 AM ...
NeuroMetrix, Inc. (NURO) announced today that it plans to issue its 2018 third quarter financial results before the opening of the market on Wednesday, October 17, 2018. The Company will host a conference call at 8:00 a.m., Eastern Time on October 17, 2018 to discuss its financial results as well as business developments affecting the Company. The conference call may be accessed in the United States by dialing 844-787-0799 and using the confirmation code 2189578.
Every investor in NeuroMetrix Inc (NASDAQ:NURO) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insiders owning Read More...
NeuroMetrix, Inc. (NURO), today reported publication of a clinical study of Quell® wearable pain relief in the Journal of Pain and Relief. The paper is titled “Real-World Evidence for the Widespread Effects of Fixed-Site High Frequency Transcutaneous Electrical Nerve Stimulation in Chronic Pain.” It is available for download at: Journal of Pain and Relief. Quell was used an average of 36 hours per week by the study participants for 60 days. Study participants reported statistically and clinically significant decreases in pain interference with activity and mood. Daily users also reported a clinically significant decrease in pain intensity and less pain interference with sleep.
NeuroMetrix, Inc. (NURO), today announced that it will showcase its latest product innovation, Quell® 2.0 Wearable Pain Relief Technology™, during a workshop at DTxDM East, and will discuss using real world, patient generated data to improve outcomes for people living with chronic pain. "We are excited to share how user feedback has helped shape innovation in our Quell technology, and how data collected from the Quell Health Cloud is fueling scientific research into chronic pain," said Frank McGillin, Senior Vice President and CCO of NeuroMetrix. Quell is an advanced, wearable technology for treating chronic pain.
WALTHAM, Mass., Sept. 20, 2018-- NeuroMetrix, Inc., reported that its President and CEO, Dr. Shai N. Gozani, yesterday participated in a discussion of the opioid crisis and the Company’ s Quell ® Wearable ...
LAS VEGAS, Sept. 4, 2018 /PRNewswire/ -- Tomorrow at PAINWeek 2018, NeuroMetrix Inc. (NURO), will unveil its latest breakthrough for the treatment of chronic pain. With economic costs estimated to be $635 billion per year, chronic pain is one of the most complex conditions for care providers and patients to manage, making it ripe for innovation. An estimated 100 million Americans are living with some form of chronic pain, and with the rise of the opioid epidemic, are increasingly searching for new, drug-free treatment methods.
NeuroMetrix, Inc. (NURO) today reported that it will be both exhibiting and sponsoring a diabetic neuropathy symposium at the 28th Annual Meeting of NEURODIAB held in Rome, Italy September 4-7. Diabetic peripheral neuropathy (DPN) is the most common complication of diabetes, affecting over half of people with diabetes. It causes significant morbidity including pain, increased risk of falling in the elderly, and is the primary trigger for diabetic foot ulcers which may require lower extremity amputations.
WALTHAM, Mass., Aug. 28, 2018-- NeuroMetrix, Inc., today reported that it will present three scientific posters at the upcoming PAINWeek 2018 National Pain Conference to be held in Las Vegas, NV, September ...
WALTHAM, Mass., Aug. 27, 2018-- NeuroMetrix, Inc. reported that the time previously announced for its presentation at the H.C.Wainwright 20 th Annual Global Investment Conference has been shifted to 10:00 ...
NeuroMetrix, Inc. (NURO) today announced it will be a presenting company at the 20th Annual Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 4 - 6, 2018, at The St. Regis New York in New York City. Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix, will provide an overview of the Company's business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference. The NeuroMetrix presentation is scheduled for Thursday, September 6, 2018 at 4:40 PM Eastern time. NeuroMetrix is an innovation driven healthcare company combining neurostimulation and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes.
NeuroMetrix, Inc. (NURO), today reported that it had achieved the second development milestone under its strategic collaboration with GSK Consumer Healthcare. A milestone payment of $3.8 Million was made by GSK. In addition, NeuroMetrix and GSK will co-fund Quell technology development for an initial two-year period starting in 2019 with extensions by mutual agreement.
LONDON, UK / ACCESSWIRE / July 25, 2018 / If you want access to our free earnings report on Intuitive Surgical, Inc. (NASDAQ: ISRG), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ISRG. The Company reported its second quarter fiscal 2018 operating and financial results on July 19, 2018. Additionally, the Company provided its guidance for FY18.
NEW YORK, NY / ACCESSWIRE / July 19, 2018 / NeuroMetrix, Inc. (NASDAQ: NURO ) will be discussing their earnings results in their Q2 Earnings Call to be held on July 19, 2018 at 8:00 AM Eastern Time. To ...
NEW YORK, NY / ACCESSWIRE / June 20, 2018 / It was a multi-year extraction agreement with Canopy Growth that sent shares of Neptune Technologies flying higher on Tuesday. Shares of NeuroMetrix also scored ...
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Neurometrix Inc (NASDAQ: NURO ) stock was trading ...